Testicular cancer

U.S. adults are still behind on routine cancer screenings—but reasons why vary by race

Retrieved on: 
Tuesday, April 2, 2024
Lung cancer, Health, Millennials, Child care, Confusion, Prostate cancer, Survival, Skin cancer, Disease, Colorectal cancer, Nervous, Risk, Cervical cancer, Heredity, Education, Patient, Cancer, Testicular cancer, Oral cancer, Generation Z, Breast cancer, Gen, Fear

The survey revealed that nearly seven in 10 U.S. adults are behind on at least one routine cancer screening.1

Key Points: 
  • The survey revealed that nearly seven in 10 U.S. adults are behind on at least one routine cancer screening.1
    The second annual survey, released during Cancer Prevention and Early Detection Month in April, indicates more U.S. adults are behind on routine cancer screenings compared to last year.
  • It is crucial to advocate for your health and talk to your health care provider about the routine cancer screenings you need.
  • “We are reaffirming our commitment to empowering people to stay ahead of cancer through prevention and early detection until all populations can achieve better outcomes—without any barriers to the process.”
    1The cancer screenings studied in this survey were for breast cancer, cervical cancer, colorectal cancer, lung cancer, oral cancer, prostate cancer, skin cancer and testicular cancer.
  • 2In this survey, Gen Z is defined as adults ages 21-27 and Millennials are defined as adults ages 28-43.

Don’t Drop the Ball! The Urology Care Foundation Urges Men to Check Themselves for Testicular Cancer Awareness Month

Retrieved on: 
Monday, April 1, 2024
Diagnosis, Health, American Urological Association, Breast, Risk, Testicular cancer, GCNIS, Medical college, Groin, Ache, Cancer, Epididymis, Scrotum, Male, Testicle, Thumb, Pain, AUA, Swelling, Courage, Birth control

BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- April is Testicular Cancer Awareness Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is urging men not to drop the ball when it comes to their testicular health.

Key Points: 
  • BALTIMORE, April 01, 2024 (GLOBE NEWSWIRE) -- April is Testicular Cancer Awareness Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), is urging men not to drop the ball when it comes to their testicular health.
  • Testicular cancer is one of the less common cancers in men, with only 1 out of every 250 men getting diagnosed during their lifetime.
  • The best way to increase the chances we can cure someone of testicular cancer is to catch it early.
  • Prostate exams, scrotal exams, penis stuff, all of it,” said C. Freeman McCluskey, MD, testicular cancer survivor and urology resident at the Medical College of Georgia.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
Thursday, February 15, 2024
Culture, Survivor, CMO, Study Group, Ototoxicity, Risk, Gesellschaft mit beschränkter Haftung, Ear, Cisplatin, Therapy, Fatigue, Life expectancy, The German, Patient, Social, Testicular cancer, Cancer, Pharmaceutical industry

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Retrieved on: 
Thursday, February 15, 2024
Culture, Survivor, CMO, Study Group, Ototoxicity, Risk, Gesellschaft mit beschränkter Haftung, Ear, Cisplatin, Therapy, Fatigue, Life expectancy, The German, Patient, Social, Testicular cancer, Cancer, Pharmaceutical industry

TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.

Key Points: 
  • TÜBINGEN, Germany, Feb. 15, 2024 /PRNewswire/ -- Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study.
  • Germ-cell testicular cancer is the most common cancer among young men, with incidence rates continuously increasing.
  • In preclinical models, ACOU085 has demonstrated its significant potential to reduce cisplatin-induced hearing loss and preserve outer hair cells from ototoxicity.
  • "The enrollment of the first patient into our ACOU085 Clinical Phase 2 program marks a further major milestone in our efforts to finally make acute and subacute forms of hearing loss treatable" said Dr. Tim Bölke, CEO and CMO of Acousia Therapeutics.

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
Wednesday, January 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.

Confusion about insurance coverage for cervical cancer screenings contributes to missed screening

Retrieved on: 
Wednesday, January 3, 2024
Testicular cancer, Affordable Care Act, PAP, Risk, Immune system, HIV/AIDS, Woman, Breast cancer, Cervical cancer, Colorectal cancer, WHO, Health, Lung cancer, HPV, Prostate cancer, Vaccination, Cancer, Skin cancer, Human papillomavirus infection, Confusion, Insurance, Letter, HIV, World Health Organization, Conditional sentence, Care Act 2014, Medicaid, Oral cancer, USPSTF, Birth control

The 2023 survey shows 41% of American women are not up to date on cervical cancer screenings.2 This indicates an urgent need to discuss the cost of cervical cancer screening, as many people may be unaware cervical cancer screenings are covered through Medicaid and most private insurance plans.

Key Points: 
  • The 2023 survey shows 41% of American women are not up to date on cervical cancer screenings.2 This indicates an urgent need to discuss the cost of cervical cancer screening, as many people may be unaware cervical cancer screenings are covered through Medicaid and most private insurance plans.
  • That means, under current law, if you have health insurance and you have a cervix, your cervical cancer screenings are covered.
  • The elimination of cervical cancer will be severely hindered without proper education across all populations about screening, insurance coverage and HPV vaccination.
  • 2The cancer screenings studied in this survey were for breast cancer, cervical cancer, colorectal cancer, oral cancer, lung cancer, prostate cancer, skin cancer and testicular cancer.

NordVPN partners with Movember and doubles donations

Retrieved on: 
Friday, December 22, 2023
Men's Health, Face, Testicular cancer, NordVPN, Mental health, Partnership, Running, Prostate cancer, Pharmaceutical industry

LONDON, Dec. 22, 2023 /PRNewswire/ -- NordVPN, a leading cybersecurity company, is proud to announce its partnership with Movember, a global movement committed to changing the face of men's health. Up until August 31, 2024, NordVPN will be supporting Movember's mission to raise awareness and contribute to the important cause of men's mental health and well-being. For some time NordVPN will also be doubling donations.

Key Points: 
  • Up until August 31, 2024, NordVPN will be supporting Movember's mission to raise awareness and contribute to the important cause of men's mental health and well-being.
  • For some time NordVPN will also be doubling donations .
  • Movember, renowned for its iconic moustache-growing campaign, focuses on addressing key issues affecting men, including mental health, suicide prevention, prostate cancer, and testicular cancer.
  • "We are excited to join forces with Movember to shed light on crucial issues that impact men's lives," said Bob Brinklow, country manager for the UK at NordVPN .

Marius Pharmaceuticals Announces KYZATREX® (CIII testosterone undecanoate capsules) HERO Campaign, Empowering Men To 'Be the Hero of Your Life Again'

Retrieved on: 
Wednesday, December 6, 2023
WCS, Hypertension, Adolescence, Testosterone, HERO, Prevalence, Ageing, Testicular cancer, Hero, Hypogonadism, Patient, Prostate cancer, Health, Veteran, Cancer, SHBG, Site, Physician, Androgen, Overalls, Pharmaceutical industry

RALEIGH, N.C., Dec. 6, 2023 /PRNewswire/ -- Marius Pharmaceuticals , a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announces the launch of its KYZATREX® HERO campaign that aims to empower men to "Be the Hero of Your Life Again."

Key Points: 
  • RALEIGH, N.C., Dec. 6, 2023 /PRNewswire/ -- Marius Pharmaceuticals , a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announces the launch of its KYZATREX® HERO campaign that aims to empower men to "Be the Hero of Your Life Again."
  • KYZATREX is an oral prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions.
  • The advertising campaign seeks to educate patients who are appropriate candidates for treatment and their physicians on how KYZATREX can help men restore testosterone levels to reinvigorate their natural vitality.
  • In a clinical efficacy study of 127 hypogonadal patients, 96% of patients taking KYZATREX had normal testosterone levels at Day 90.

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Neoplasm, Nivolumab, MSI, Cell, Testicular cancer, Memorial Sloan Kettering Cancer Center, Neurotoxicity, SITC, Immunotherapy, Cytokine release syndrome, Mink, Annual general meeting, Lung cancer, Society, Cancer, Therapy, Patient, HLA, Failure, Phosphorus, Vaccine, Pharmaceutical industry, Medical imaging

AgenT-797 showed long-term persistence and induced a potent anti-tumor response, including increased infiltration of cytotoxic immune cells into tumors.

Key Points: 
  • AgenT-797 showed long-term persistence and induced a potent anti-tumor response, including increased infiltration of cytotoxic immune cells into tumors.
  • AgenT-797 was detected in the periphery for up to 6 months and persistence was independent of HLA matching.
  • An increased level of immune cell tumor infiltration and neoantigen driven expansion of anti-tumor cytotoxic T cells was observed following administration.
  • Expansion of clinical programs are underway in additional solid tumor settings, including relapsed/refractory gastric cancer.

Mangoceuticals, Inc. Launches Charitable Initiative in Support of Men’s Health Awareness Month

Retrieved on: 
Thursday, November 2, 2023
American Cancer Society, Sale, Erectile dysfunction, Education, Health, Organization, Research, Prostate cancer, Testicular cancer, Estate (law), Organic, Marketing, Tumbler, Cancer, Prostate, Pharmaceutical industry, Dietary supplement

Throughout November, a month dedicated to raising awareness of men’s health issues, MangoRx will donate 50 percent of all branded merchandise profits to select charitable organizations that focus on supporting education and awareness around subjects such as prostate cancer, testicular cancer, and men’s suicide.

Key Points: 
  • Throughout November, a month dedicated to raising awareness of men’s health issues, MangoRx will donate 50 percent of all branded merchandise profits to select charitable organizations that focus on supporting education and awareness around subjects such as prostate cancer, testicular cancer, and men’s suicide.
  • MangoRx dedicates its business to shattering stigmas surrounding men’s health and wellness by making advanced solutions approachable, innovative, and unapologetically fun.
  • “MangoRx empowers men to take control of their health and overall well-being,” said Jacob Cohen, MangoRx Co-Founder and CEO.
  • About one in eight men will be diagnosed with prostate cancer during his lifetime, and it’s MangoRx’s mission to create awareness and facilitate action.